280 related articles for article (PubMed ID: 28901490)
1. Targeting strategies of adenovirus‑mediated gene therapy and virotherapy for prostate cancer (Review).
Cai Z; Lv H; Cao W; Zhou C; Liu Q; Li H; Zhou F
Mol Med Rep; 2017 Nov; 16(5):6443-6458. PubMed ID: 28901490
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus-based therapy for prostate cancer.
Ekblad M; Halldén G
Curr Opin Mol Ther; 2010 Aug; 12(4):421-31. PubMed ID: 20677093
[TBL] [Abstract][Full Text] [Related]
3. Virus, Oncolytic Virus and Human Prostate Cancer.
Liu GB; Zhao L; Zhang L; Zhao KN
Curr Cancer Drug Targets; 2017; 17(6):522-533. PubMed ID: 27993115
[TBL] [Abstract][Full Text] [Related]
4. Cell-selective gene silencing in prostate cancer LNCap cells using prostate-specific membrane antigen promoter and enhancer in vitro and in vivo.
Liu R; Sun J; Zhang Z; Xu Y
Cell Biol Int; 2012 Oct; 36(10):863-72. PubMed ID: 22612256
[TBL] [Abstract][Full Text] [Related]
5. Adenovirus-mediated cancer gene therapy and virotherapy (Review).
Fukazawa T; Matsuoka J; Yamatsuji T; Maeda Y; Durbin ML; Naomoto Y
Int J Mol Med; 2010 Jan; 25(1):3-10. PubMed ID: 19956895
[TBL] [Abstract][Full Text] [Related]
6. Prostate specific membrane antigen (PSMA) is a tissue-specific target for adenoviral transduction of prostate cancer in vitro.
Kraaij R; van Rijswijk AL; Oomen MH; Haisma HJ; Bangma CH
Prostate; 2005 Feb; 62(3):253-9. PubMed ID: 15389777
[TBL] [Abstract][Full Text] [Related]
7. Gene therapy for prostate cancer by controlling adenovirus E1a and E4 gene expression with PSES enhancer.
Li X; Zhang YP; Kim HS; Bae KH; Stantz KM; Lee SJ; Jung C; Jiménez JA; Gardner TA; Jeng MH; Kao C
Cancer Res; 2005 Mar; 65(5):1941-51. PubMed ID: 15753394
[TBL] [Abstract][Full Text] [Related]
8. Fas ligand delivery by a prostate-restricted replicative adenovirus enhances safety and antitumor efficacy.
Li X; Liu YH; Zhang YP; Zhang S; Pu X; Gardner TA; Jeng MH; Kao C
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5463-73. PubMed ID: 17875776
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cells serve as a "Trojan horse" for oncolytic adenovirus delivery in the treatment of mouse prostate cancer.
Li ZL; Liang X; Li HC; Wang ZM; Chong T
Acta Pharmacol Sin; 2016 Aug; 37(8):1121-8. PubMed ID: 27345628
[TBL] [Abstract][Full Text] [Related]
10. Recombinant adenovirus mediated prostate-specific enzyme pro-drug gene therapy regulated by prostate-specific membrane antigen (PSMA) enhancer/promoter.
Zeng H; Wei Q; Huang R; Chen N; Dong Q; Yang Y; Zhou Q
J Androl; 2007; 28(6):827-35. PubMed ID: 17522418
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of continuous low dose rate versus acute single high dose rate radiation combined with oncolytic viral therapy for prostate cancer.
Liu C; Zhang Y; Liu MM; Zhou H; Chowdhury W; Lupold SE; Deweese TL; Rodriguez R
Int J Radiat Biol; 2010 Mar; 86(3):220-9. PubMed ID: 20201650
[TBL] [Abstract][Full Text] [Related]
12. Comparison of prostate-specific promoters and the use of PSP-driven virotherapy for prostate cancer.
Lu Y; Zhang Y; Chang G; Zhang J
Biomed Res Int; 2013; 2013():624632. PubMed ID: 23484134
[TBL] [Abstract][Full Text] [Related]
13. Targeting the prostate-specific membrane antigen for prostate cancer therapy.
Bühler P; Wolf P; Elsässer-Beile U
Immunotherapy; 2009 May; 1(3):471-81. PubMed ID: 20635963
[TBL] [Abstract][Full Text] [Related]
14. Specific targeting of prostate cancer cells in vitro by the suicide gene/prodrug system, uracil phosphoribosyltransferase/5-fluorouracil, under the control of prostate-specific membrane antigen promoter/enhancer.
Zhao FJ; Zhang S; Yu ZM; Xia SJ; Li H
Prostate Cancer Prostatic Dis; 2009; 12(2):166-71. PubMed ID: 18626508
[TBL] [Abstract][Full Text] [Related]
15. Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer.
Lee SJ; Zhang Y; Lee SD; Jung C; Li X; Kim HS; Bae KH; Jeng MH; Kao C; Gardner T
Mol Ther; 2004 Dec; 10(6):1051-8. PubMed ID: 15564137
[TBL] [Abstract][Full Text] [Related]
16. Chapter four--Design of improved oncolytic adenoviruses.
Alemany R
Adv Cancer Res; 2012; 115():93-114. PubMed ID: 23021243
[TBL] [Abstract][Full Text] [Related]
17. Tissue-selective RNA interference in prostate cancer cell using prostate specific membrane antigen promoter/enhancer.
Zhao W; Xu Y; Kong D; Liu R; Zhang Z; Jin C; Zhang Z; Xiu Y
Urol Oncol; 2009; 27(5):539-47. PubMed ID: 18639471
[TBL] [Abstract][Full Text] [Related]
18. Novel system uses probasin-based promoter, transcriptional silencers and amplification loop to induce high-level prostate expression.
Woraratanadharm J; Rubinchik S; Yu H; Dong JY
BMC Biotechnol; 2007 Feb; 7():9. PubMed ID: 17295927
[TBL] [Abstract][Full Text] [Related]
19. A novel capsid-modified oncolytic recombinant adenovirus type 5 for tumor-targeting gene therapy by intravenous route.
Wang Z; Yu B; Wang B; Yan J; Feng X; Wang Z; Wang L; Zhang H; Wu H; Wu J; Kong W; Yu X
Oncotarget; 2016 Jul; 7(30):47287-47301. PubMed ID: 27323824
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the multidrug-resistant phenotype by targeting YB-1 with a conditionally oncolytic adenovirus: implications for combinatorial treatment regimen with chemotherapeutic agents.
Mantwill K; Köhler-Vargas N; Bernshausen A; Bieler A; Lage H; Kaszubiak A; Surowiak P; Dravits T; Treiber U; Hartung R; Gansbacher B; Holm PS
Cancer Res; 2006 Jul; 66(14):7195-202. PubMed ID: 16849566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
